Published in
Karger Publishers, European Thyroid Journal, 3(5), p. 187-194
DOI: 10.1159/000448919
Links
- ORCID
- Karger Publishers | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
Journal article published in 2016 by
Lars Bastholt,
Yi Wu,
Alan Webster,
Michael C. Kreissl,
Dagmar Führer,
Laura D. Locati,
Léa Maciel,
Ana Luiza Maia 
,
Kevin N. Heller,
Rossella Elisei
,
Kevin N. Heller,
Rossella Elisei
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher.